Free Trial
LON:DPH

Dechra Pharmaceuticals (DPH) Share Price, News & Analysis

Dechra Pharmaceuticals logo
GBX 3,866 0.00 (0.00%)
(As of 01/16/2024)

About Dechra Pharmaceuticals Stock (LON:DPH)

Key Stats

Today's Range
3,866
3,866
50-Day Range
3,866
3,866
52-Week Range
2,473.32
4,145.84
Volume
2.04 million shs
Average Volume
1.29 million shs
Market Capitalization
£4.40 billion
P/E Ratio
N/A
Dividend Yield
1.16%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. It also provides water soluble antibiotics, vaccines, lameness, pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. In addition, the company distributes veterinary pharmaceuticals and equipment; markets pet diets; and develops, regulates, manufactures, and markets crop protection, as well as offers financial services. It markets its products through wholesaler and distributor networks. The company operates in the United Kingdom, Germany, rest of Europe, the United States, and internationally. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.

Receive DPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dechra Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DPH Stock News Headlines

Dechra Pharmaceuticals PLC (DPH.L)
What Comes Next Could Be a Once-in-a-Lifetime Opportunity
A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.
Form 8.3 - Dechra Phartmaceuticals PLC - Amendment
Dechra Pharmaceuticals PLC DPH
See More Headlines

DPH Stock Analysis - Frequently Asked Questions

Dechra Pharmaceuticals' stock was trading at GBX 3,858 at the start of the year. Since then, DPH shares have increased by 0.2% and is now trading at GBX 3,866.
View the best growth stocks for 2024 here
.

Shares of DPH stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dechra Pharmaceuticals investors own include 32Red (TTR), 1428686 (SGP.L) (SGP), JD Sports Fashion (JD), Ashtead Group (AHT), Rolls-Royce Holdings plc (RR.L), Cranswick (CWK) and Drax Group (DRX).

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
Personal Services
CIK
N/A
Fax
N/A
Employees
2,457
Year Founded
N/A

Profitability

Net Income
£-27,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£761.50 million
Cash Flow
GBX 158.24 per share
Book Value
GBX 663 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.40 billion
Optionable
Not Optionable
Beta
0.78
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (LON:DPH) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners